Profile data is unavailable for this security.
About the company
Neuland Laboratories Ltd. is a global provider of active pharmaceutical ingredients (APIs) contract development and manufacturing organization (CDMO) services. It is focused on manufacture and sale of active pharmaceutical ingredients and allied services. It supports biotechnology and pharmaceutical companies in the design, development and manufacturing of complex APIs. It has two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). It develops and manufactures non-exclusive APIs both Prime APIs comprising large volume, mature molecules, and specialty APIs comprising lower volume, complex molecules with less competition. It develops small molecules and peptides for clinical trials and beyond. It provides an end-to-end continuum of customized services from early-stage drug development (Pre-IND) through to commercial manufacturing of complex APIs, including process development, process optimization, analytical testing, and regulatory support.
- Revenue in INR (TTM)15.75bn
- Net income in INR1.79bn
- Incorporated1984
- Employees1.80k
- LocationNeuland Laboratories Ltd'A' Block, Ground Floor, 8-2-120/113Rd No 2, Banjara Hills, Sanali Info ParkHYDERABAD 500033IndiaIND
- Phone+91 4 067611600
- Fax+91 4 067611600
- Websitehttps://www.neulandlabs.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Consumer Healthcare India Ltd | 8.16bn | 2.18bn | 98.81bn | 583.00 | 45.35 | -- | 43.49 | 12.10 | 94.62 | 94.62 | 354.49 | -- | -- | -- | -- | 14,003,430.00 | -- | -- | -- | -- | 75.05 | -- | 26.69 | -- | -- | 143.16 | -- | -- | 30.45 | -- | 9.76 | -- | -- | -- |
| Alivus Life Sciences Ltd | 25.12bn | 5.44bn | 112.89bn | 2.20k | 20.80 | -- | 18.36 | 4.49 | 44.23 | 44.23 | 204.37 | -- | -- | -- | -- | 11,403,810.00 | -- | 17.43 | -- | 23.95 | 57.08 | 53.29 | 21.64 | 20.24 | -- | 133.39 | -- | 27.09 | 4.54 | 9.20 | 3.13 | 9.18 | 26.57 | -- |
| Cohance Lifesciences Ltd | 20.51bn | 2.02bn | 120.74bn | 1.21k | 54.40 | -- | 35.16 | 5.89 | 5.80 | 5.80 | 58.32 | -- | -- | -- | -- | 16,926,160.00 | -- | 18.62 | -- | 20.90 | 71.62 | 60.82 | 8.80 | 30.28 | -- | 7.07 | -- | 15.59 | 13.91 | 7.51 | -10.79 | -3.31 | 9.39 | -- |
| Concord Biotech Ltd | 11.59bn | 3.12bn | 123.91bn | 1.57k | 39.86 | -- | 32.55 | 10.69 | 29.71 | 29.71 | 110.27 | -- | -- | -- | -- | 7,375,525.00 | -- | 18.47 | -- | 20.61 | 57.97 | 67.80 | 26.85 | 30.22 | -- | -- | -- | 20.68 | 18.01 | 18.56 | 20.62 | 17.06 | -6.49 | -- |
| Caplin Point Laboratories Ltd | 20.89bn | 6.14bn | 131.59bn | 990.00 | 21.51 | -- | 18.98 | 6.30 | 80.49 | 80.49 | 274.05 | -- | -- | -- | -- | 21,105,860.00 | -- | 19.10 | -- | 21.90 | 60.67 | 54.95 | 29.77 | 26.11 | -- | 1,127.02 | -- | 8.93 | 14.37 | 17.55 | 17.33 | 20.06 | 20.07 | 19.14 |
| Granules India Ltd | 50.92bn | 5.45bn | 136.46bn | 4.07k | 25.02 | -- | 16.57 | 2.68 | 22.48 | 22.48 | 209.84 | -- | -- | -- | -- | 12,524,500.00 | -- | 10.20 | -- | 15.66 | 64.46 | 50.89 | 10.71 | 11.64 | -- | 6.98 | -- | 8.72 | -0.5494 | 11.52 | 23.74 | 9.64 | 25.38 | 8.45 |
| Jubilant Pharmova Ltd | 79.18bn | 4.33bn | 144.59bn | 978.00 | 33.53 | -- | 17.04 | 1.83 | 27.23 | 27.23 | 498.28 | -- | -- | -- | -- | 80,965,230.00 | -- | 3.37 | -- | 4.02 | 67.71 | 64.54 | 5.42 | 5.64 | -- | 4.06 | -- | 21.60 | 7.93 | 3.90 | 988.72 | 6.73 | 14.21 | 0.00 |
| Natco Pharma Ltd | 45.60bn | 15.57bn | 147.56bn | 4.20k | 9.48 | -- | 8.20 | 3.24 | 86.94 | 86.94 | 254.62 | -- | -- | -- | -- | 10,860,210.00 | -- | 15.82 | -- | 18.14 | 82.79 | 75.22 | 33.87 | 30.39 | -- | 44.51 | -- | 12.09 | 10.77 | 18.26 | 35.81 | 32.55 | 7.37 | -2.33 |
| Alembic Pharmaceuticals Ltd | 72.67bn | 6.29bn | 151.33bn | 16.57k | 24.01 | -- | 16.36 | 2.08 | 32.06 | 32.06 | 370.42 | -- | -- | -- | -- | 4,385,258.00 | -- | 9.51 | -- | 12.59 | 72.71 | 65.30 | 8.61 | 10.84 | -- | 8.89 | -- | 33.08 | 7.12 | 7.69 | -5.26 | -6.78 | -5.17 | 9.46 |
| Neuland Laboratories Ltd | 15.75bn | 1.79bn | 167.51bn | 1.80k | 93.51 | -- | 63.77 | 10.63 | 139.62 | 139.62 | 1,227.57 | -- | -- | -- | -- | 8,755,392.00 | -- | 11.09 | -- | 14.93 | 49.33 | 49.56 | 11.37 | 14.20 | -- | 12.29 | -- | 6.80 | -5.24 | 14.13 | -13.32 | 45.82 | 33.44 | 43.10 |
| Sai Life Sciences Ltd | 21.70bn | 3.33bn | 193.61bn | 3.40k | 59.13 | -- | 39.35 | 8.92 | 15.47 | 15.47 | 100.85 | -- | -- | -- | -- | 6,380,065.00 | -- | -- | -- | -- | 73.41 | -- | 15.34 | -- | -- | 10.74 | -- | -- | 15.66 | -- | 105.45 | -- | -- | -- |
| Eris Lifesciences Ltd | 30.78bn | 4.31bn | 195.93bn | 3.56k | 44.74 | -- | 25.84 | 6.37 | 31.61 | 31.61 | 225.62 | -- | -- | -- | -- | 8,651,377.00 | -- | 9.98 | -- | 13.50 | 74.64 | 77.74 | 15.28 | 20.85 | -- | 4.06 | -- | -- | 44.02 | 21.92 | -10.24 | 3.48 | 0.4868 | -- |
| Piramal Pharma Ltd | 88.71bn | -1.64bn | 219.61bn | 7.13k | -- | -- | 31.74 | 2.48 | -1.26 | -1.26 | 66.90 | -- | -- | -- | -- | 12,449,300.00 | -- | -- | -- | -- | 64.63 | -- | -1.84 | -- | -- | 0.5519 | -- | -- | 11.99 | -- | 411.39 | -- | -- | -- |
| Astrazeneca Pharma India Ltd | 21.77bn | 2.01bn | 222.98bn | 802.00 | 110.96 | -- | 92.31 | 10.24 | 80.38 | 80.38 | 871.22 | -- | -- | -- | -- | 27,150,250.00 | -- | 11.06 | -- | 18.24 | 42.78 | 49.98 | 9.23 | 9.43 | -- | 78.86 | -- | 38.57 | 32.48 | 15.59 | -28.34 | 9.89 | -34.23 | 100.00 |
| Wockhardt Ltd | 31.51bn | 220.00m | 226.64bn | 2.30k | 1,054.18 | -- | 96.44 | 7.19 | 1.32 | 1.32 | 194.54 | -- | -- | -- | -- | 13,723,870.00 | -- | -4.37 | -- | -7.67 | 65.92 | 56.50 | 0.2539 | -11.98 | -- | 1.23 | -- | -- | 7.65 | 1.15 | 89.85 | -- | 16.19 | -- |
| Pfizer Ltd | 24.82bn | 8.54bn | 230.45bn | 1.60k | 27.00 | -- | 25.24 | 9.28 | 186.60 | 186.60 | 542.67 | -- | -- | -- | -- | 15,533,980.00 | -- | 15.22 | -- | 18.50 | 65.10 | 61.73 | 34.39 | 25.99 | -- | 83.13 | -- | 50.95 | 4.02 | 1.18 | 39.23 | 8.56 | -6.02 | 28.47 |
Data as of Feb 16 2026. Currency figures normalised to Neuland Laboratories Ltd's reporting currency: Indian Rupee INR
14.89%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 04 Feb 2026 | 320.98k | 2.50% |
| ICICI Prudential Asset Management Co. Ltd. (Invt Mgmt)as of 31 Jan 2026 | 305.39k | 2.38% |
| HSBC Asset Management (India) Pvt Ltd.as of 31 Dec 2025 | 233.70k | 1.82% |
| Jupiter Asset Management Ltd.as of 31 Oct 2025 | 223.74k | 1.74% |
| Bajaj Finserv Asset Management Ltd.as of 31 Jan 2026 | 190.83k | 1.49% |
| Mahindra Manulife Investment Management Pvt Ltd.as of 31 Jan 2026 | 176.41k | 1.38% |
| Matthews International Capital Management LLCas of 30 Jun 2025 | 133.38k | 1.04% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 110.44k | 0.86% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 108.63k | 0.85% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 106.63k | 0.83% |
More ▼
Data from 31 Dec 2025 - 31 Jan 2026Source: FactSet Research Systems Inc.
